Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2022 | Improving immunotherapy for the treatment of patients with ovarian cancer

Benoit You • 5 Jun 2022
ASCO 2022
Gynecological Cancer Ovarian Cancer

Benoit You, MD, PhD, Centre Hospitalier Lyon-Sud, Saint-Genis-Laval, France, discusses how immunotherapy (IO) could be improved for the treatment of ovarian cancer. IO has thus far not been so successful in patients with ovarian cancer. A better selection process of which patients will benefit could improve IO success rates and utilizing the CA-125 ELIMination rate constant K (KELIM). This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.

More from Benoit You

1:01
ESMO 2023 highlights in the treatment of ovarian cancer
Benoit You • 23 Oct 2023
1:15
The influence of HRD testing in precision medicine
Benoit You • 23 Oct 2023
1:37
Updates in ICIs and ADCs in cervical cancer
Benoit You • 23 Oct 2023
1:21
Evaluating the interchangeability of HRD testing in ovarian cancer
Benoit You • 23 Oct 2023

Related Videos

0:39
Early diagnosis of ovarian cancer with Pap smears
Sergio Marchini • 8 Apr 2024
0:46
FRa expression and sequencing ADCs in endometrial cancer
Rebecca Porter • 8 Apr 2024
4:12
PETRA: saruparib in solid tumors with BRCA1/2, PALB2 or RAD51C/D mutations
Timothy Yap • 7 Apr 2024
1:11
Clonal hematopoiesis mutations in ovarian carcinomas
Rebecca Porter • 8 Apr 2024
The content of VJOncology is intended for healthcare professionals